Acetaldehyde

Acetaldehyde

SCHEMBL308459

CC=O.Oc1ccc2[nH]ccc2c1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.78
GAA P10253 1/20 0.78
ALOX15 P16050 1/20 0.78
RAD51 Q06609 1/20 0.78
NPSR1 Q6W5P4 1/20 0.78
TYR P14679 1/20 0.55
CYP2A6 P11509 3/20 0.55
MAOB P27338 2/20 0.47
AHR P35869 3/20 0.46
NR4A2 P43354 2/20 0.46
F7 P08709 1/20 0.46
LTA4H P09960 1/20 0.46
F3 P13726 1/20 0.46
MAPT P10636 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
GUSB P08236 2/20 0.44
F2 P00734 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29440252 0.88 USP2 (1.00) USP2GAAALOX15RAD51NPSR1
SCHEMBL50566 0.88 USP2 (1.00) USP2GAAALOX15RAD51NPSR1
Water SCHEMBL28220544 0.86 USP2 (0.95) USP2GAAALOX15RAD51NPSR1
Bromide SCHEMBL6029763 0.86 USP2 (0.95) USP2GAAALOX15RAD51NPSR1
Hydrochloric Acid SCHEMBL4718421 0.86 USP2 (0.95) USP2GAAALOX15RAD51NPSR1
Acetic Acid SCHEMBL122895 0.85 USP2 (0.78) USP2GAAALOX15RAD51NPSR1
Tert-Butyl Formate SCHEMBL27623661 0.84 USP2 (0.64) USP2GAAALOX15RAD51NPSR1
Ethoxycarbonyl Group SCHEMBL27597884 0.82 GAA (0.62) USP2GAAALOX15RAD51NPSR1
SCHEMBL5447196 0.81 TYR (0.84) USP2GAAALOX15RAD51NPSR1
SCHEMBL4542260 0.81 USP2 (0.70) USP2GAAALOX15RAD51NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473199-A1 ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS Brain Watch Ltd. (IL) 2012-07-11 EP claimed
US-20120156139-A1 ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEROF FOR DIAGNOSING CONDITIONS AND DISORDERS BRAIN WATCH LTD. (IL) 2012-06-21 US claimed
WO-2011024156-A1 ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS BRAIN WATCH LTD. (IL) 2011-03-03 WO claimed
US-20080287774-A1 Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof BRAIN WATCH LTD. (IL) 2008-11-20 US claimed
EP-4627069-A1 FOOD AND PHARMACEUTICAL COMPOSITION FOR DETOXIFYING ENDOGENOUS ALDEHYDES Picoentech Co., Ltd. (KR) 2025-10-08 EP disclosed
WO-2024117698-A1 FOOD AND PHARMACEUTICAL COMPOSITION FOR DETOXIFYING ENDOGENOUS ALDEHYDES PICOENTECH Co., LTD. (KR) 2024-06-06 WO disclosed
US-20240182915-A1 FOOD AND PHARMACEUTICAL COMPOSITION FOR DETOXIFYING ENDOGENOUS ALDEHYDES PICOENTECH Co., LTD. (KR) 2024-06-06 US disclosed
US-20170240652-A1 ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF NESTEC S.A. (CH) 2017-08-24 US disclosed
US-9673030-B2 Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry EMORY UNIVERSITY (US) 2017-06-06 US disclosed
US-9364474-B2 Method for treatment of neurologic dysfunction MEDDEV INC. (US) 2016-06-14 US disclosed
EP-3004068-A2 PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS Nestec S.A. (CH) 2016-04-13 EP disclosed
US-20140018382-A1 Method for treament of neurologic dysfunction MedDEV, Inc. (US) 2014-01-16 US disclosed
US-20090029993-A1 METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN LEXICON PHARMACEUTICALS, INC. 2009-01-29 US disclosed
US-20090005381-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS LEXICON PHARMACEUTICALS, INC. 2009-01-01 US disclosed
US-20090005382-A1 METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS TERSERA THERAPEUTICS LLC 2009-01-01 US disclosed
WO-2009002964-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS LEXICON PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
WO-2009002970-A1 COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS LEXICON PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
US-20080287774-A1 Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof BRAIN WATCH LTD. (IL) 2008-11-20 US disclosed
EP-1948248-A2 MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY MEANS AND METHODS THEREOF Katz-Brull, Rachel (IL) 2008-07-30 EP disclosed
WO-2007052274-A2 MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY MEANS AND METHODS THEREOF BRAIN WATCH LTD. (IL) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240652-A1 ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF TPH1, HTR5A, KYNU USP2 3713/4885GAA 3364/4885ALOX15 329/4885
US-20090005381-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS TPH1, TPH2, HNMT USP2 2325/4885GAA 218/4885ALOX15 354/4885
US-20090029993-A1 METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN TPH1, TPH2, HNMT USP2 1877/4885GAA 445/4885ALOX15 552/4885
US-20090005382-A1 METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, MAOB USP2 935/4885GAA 369/4885ALOX15 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.